Omburtamab is a Monoclonal Antibody Conjugated owned by Y-mAbs Therapeutics, and is involved in 10 clinical trials, of which 3 were completed, 6 are ongoing, and 1 is planned.
Monoclonal antibody conjugate elicits anticancer activity. B7H3 (CD276) is expressed on the cell membranes of a wide variety of tumors of neuroectodermal, mesenchymal and epithelial origin and is highly expressed on monocyte-derived dendritic cells (mdDCs). the therapeutic candidate inhibits T-cell activation and the production of effector cytokines such as interferon-gamma and interleukin-4 and exhibits therapeutic intervention.
The revenue for Omburtamab is expected to reach a total of $113m through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Omburtamab NPV Report.
Omburtamab was originated by Memorial Sloan Kettering Cancer Center and is currently owned by Y-mAbs Therapeutics. SciClone Pharmaceuticals Holdings is the other company associated in development or marketing of Omburtamab.
Monoclonal antibody conjugate is under development for the treatment of refractory central nervous system (brain) tumor, atypical teratoid rhabdoid tumor, leptomeningeal neoplasms, neuroblastoma metastatic, adrenocortical carcinoma, ependymoma, sarcomas, melanoma, medulloblastoma, primitive neuroectodermal tumor (PNET), pediatric diffuse intrinsic pontine glioma, desmoplastic small round cell tumor of peritoneum and Wilms' tumor. It is administered through intrathecal, intraperitoneal and intracerebroventricular routes. The monoclonal antibody 8H9 is an IgG1 antibody and it is tagged with 131I, 124I, to elicit radioactivity towards tumor cells, with specificity for B7H3 antigen. B7-H3, assigned as CD276 is a type I trans-membrane protein structurally related to the B7 family of ligands by the presence of a single set of immunoglobulin-V-like and immunoglobulin-C-like (VC) domains. It acts by targeting the CD276 antigen. It was also under development for ovarian cancer and retinoblastoma.
It was under investigation for the treatment of metastatic brain cancer.
SciClone Pharmaceuticals Holdings Overview
SciClone Pharmaceuticals Holdings (SciClone) develops and commercializes products for the treatment of cancer and immunology. The company’s pipe line products include daya sin, zotye, nomic, angel, ando student, he lesheng, mesna, methotrexate injection, algos and faroda among others. Its under-development products comprise Naxitamab, Circumcising, Vibativ, Vaborem, RRx-001, PEN-866, PT-112, ABTL-0812 and HSP90-PI3K. It also markets Zadaxin (Thymalfasin), an immunostimulatory agent indicated for the treatment of hepatitis as an immune system enhancer. SciClone is headquartered in Hongkong.
The company reported revenues of (Renminbi) CNY2,518.5 million for the fiscal year ended December 2021 (FY2021), an increase of 31.3% over FY2020. In FY2021, the company’s operating margin was 42%, compared to an operating margin of 43.5% in FY2020. In FY2021, the company recorded a net margin of 36.7%, compared to a net margin of 39.3% in FY2020.
Quick View – Omburtamab
|Highest Development Stage|